KROS
Keros Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.06
+3.75%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 123.29x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 0.84x
- Price / sales
- 14.61x
- Price / cash flow
- -4.57x
Enterprise value
- Enterprise value
- -$22.6M
- EV / sales
- -1.50x
- EV / EBITDA
- 0.27x
- EV / EBIT
- 0.22x
- Market cap
- $219.3M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026